 Castle Biosciences, Inc. Nasdaq: CSTL, a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an independent, systematic review and meta-analysis demonstrating that its DecisionDx-Melanoma test is a significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma. 